We apply institutional policies and procedures
We follow data protection policies of Institut Pasteur
We do due diligence for all prospectively acquired strains. We provide all available information, for both prospectively acquired and historical strains, to end users of microbial strains. We do not consider genomic data of strains to be in the scope of Nagoya Protocol, except if the country of origin’s ABS regulations explicitly state otherwise. We consider isolated strains only, and not primary human specimens (e.g. fecal samples), to be in the scope of NP. Human-origin specimens are not considered to be in the scope of NP, even if they may contain molecules, such as antibodies, that are produced as a specific immune response to a microorganism.
Our Project Management Office takes care of all declaration and authorization procedures according to national regulations. This includes a "Transparency Portal" with short information about research projects that have made use of collections from CHIP. Description of other projects can be found here or here.
We follow the Gender Equality Plan of Institut Pasteur. The CRBIP Director and three of the four Heads of Units are women.
The Transparency portal includes summary information on research projects that have used or will be using human biological resources.